id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-6736-0005,FDA,FDA-2017-E-6736,"Determination of Regulatory Review Period for Purposes of Patent
Extension; XERMELO",Notice,Determinations,2018-12-28T05:00:00Z,2018,12,2018-12-28T05:00:00Z,2019-02-27T04:59:59Z,2018-12-31T21:26:53Z,2018-28218,0,0,09000064839cbee3
FDA-2017-E-6736-0004,FDA,FDA-2017-E-6736,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T12:51:21Z,,0,0,090000648378a8fc
FDA-2017-E-6736-0003,FDA,FDA-2017-E-6736,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2018-01-12T05:00:00Z,2018,1,2018-01-12T05:00:00Z,,2018-01-12T19:48:39Z,,0,0,0900006482df07a9